Abstract
Sodium glucose cotransporter 2 (SGLT 2) inhibitors, also called gliflozins, are the last drug group on the market to treat type 2 diabetes mellitus. Their representatives are canagliflozin, dapagliflozin, empagliflozin and ertugliflozin, of which the first three are also available in the Czech Republic.
The mechanism of action is inhibition of glucose reabsorption in the kidney leading to glycosuria. The most common side effect is genital fungal infections, with some studies showing a slightly higher incidence of urinary tract infections.
Their treatment is standard, discontinuation of gliflozins during normal treatment is not necessary. The course of treatment does not differ from the usual standards, gliflozin is of course recommended to stop and treat diabetes with another type of antidiabetic drug.
This complication of gliflozin treatment is very rare. However, due to the fact that it is demonstrated in a significantly higher than usual percentage in women, and due to the increasing use of gliflozins (for their positive effects) in the treatment of type 2 diabetes mellitus, we consider it appropriate to draw attention to it.